We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Based Image Analysis Module to Aid Cancer Detection in Bronchoscopic Lung Biopsies

By LabMedica International staff writers
Posted on 22 Aug 2024

Bronchoscopy guidelines generally advocate for the use of rapid on-site evaluation (ROSE) during lung biopsies to determine lung cancer, but this requires a cytologist or a highly trained cytotechnician to be physically present, limiting its availability at many centers due to resource constraints. Now, a novel system promising fast, in-room, accurate identification of tissue that is suspicious for cancer can fill in the gaps by extending the benefits of ROSE to the proceduralist when the service is not available due to staff limitations.

Invenio Imaging (Santa Clara, CA, USA) has completed enrolment for a pivotal trial in collaboration with Johnson & Johnson (New Brunswick, NJ, USA) aimed at gaining FDA approval for its AI-powered software that identifies lung cancer. The trial, named the ON-SITE study, is being conducted at two university centers in Texas and North Carolina. It seeks to develop and validate an AI-based image analysis module for Invenio’s NIO Laser Imaging System, which enhances lung imaging by accelerating the creation and analysis of digital images. The NIO system enables more operational flexibility by allowing hospital staff to quickly image fresh tissue biopsies in settings where such capabilities were previously unavailable. The system simplifies sample preparation, as it requires no staining or sectioning and can be managed by existing operating room personnel.

“AI aiding healthcare may seem utopic, but the future is coming,” said Gustavo Cumbo-Nacheli, principal investigator for the ON-SITE study. “While still investigational, the promise of fast, in-room, accurate identification of tissue that is suspicious for cancer has the potential to ultimately lead to improved outcomes, a beneficial cost to benefit profile, and personalized treatments.”

Related Links:
Invenio Imaging
Johnson & Johnson

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Refrigerated Microtube Homogenizer
BeadBlaster 24R
New
Toxoplasma Rapid Test
Toxo IgG/IgM Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The DNA sequencing method indentifies the bacterial causes of infections to determine the most effective antibiotics for treatment (Photo courtesy of Shutterstock)

New DNA Test Diagnoses Bacterial Infections Faster and More Accurately

Antimicrobial resistance has emerged as a significant global health threat, causing at least one million deaths annually since 1990. The Global Research on Antimicrobial Resistance (GRAM) Project warns... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.